Magenta Therapeutics Stock Operating Margin
| MGTADelisted Stock | USD 0.82 0.03 3.80% |
Magenta Therapeutics fundamentals help investors to digest information that contributes to Magenta Therapeutics' financial success or failures. It also enables traders to predict the movement of Magenta Stock. The fundamental analysis module provides a way to measure Magenta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Magenta Therapeutics stock.
Magenta |
Magenta Therapeutics Company Operating Margin Analysis
Magenta Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Magenta Therapeutics has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Magenta Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Magenta Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Magenta Therapeutics could also be used in its relative valuation, which is a method of valuing Magenta Therapeutics by comparing valuation metrics of similar companies.Magenta Therapeutics is currently under evaluation in operating margin category among its peers.
Magenta Fundamentals
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 | |||
| Current Valuation | (32.66 M) | |||
| Shares Outstanding | 60.66 M | |||
| Shares Owned By Insiders | 2.23 % | |||
| Shares Owned By Institutions | 62.63 % | |||
| Number Of Shares Shorted | 383.03 K | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 0.54 X | |||
| EBITDA | (78.98 M) | |||
| Net Income | (76.46 M) | |||
| Cash And Equivalents | 128.28 M | |||
| Cash Per Share | 2.13 X | |||
| Total Debt | 29.96 M | |||
| Debt To Equity | 0.25 % | |||
| Current Ratio | 10.22 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (67.09 M) | |||
| Short Ratio | 1.38 X | |||
| Earnings Per Share | (1.11) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 67 | |||
| Beta | 2.12 | |||
| Market Capitalization | 45.14 M | |||
| Total Asset | 146.65 M | |||
| Retained Earnings | (402.03 M) | |||
| Working Capital | 101.05 M | |||
| Current Asset | 33.34 M | |||
| Current Liabilities | 3.39 M | |||
| Z Score | -3.88 | |||
| Net Asset | 146.65 M |
About Magenta Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Magenta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Magenta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Magenta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Magenta Stock
If you are still planning to invest in Magenta Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Magenta Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |